» Articles » PMID: 26232617

Involvement of MiR-34c in High Glucose-insulted Mesenchymal Stem Cells Leads to Inefficient Therapeutic Effect on Myocardial Infarction

Overview
Journal Cell Signal
Date 2015 Aug 2
PMID 26232617
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

High glucose-insulted bone marrow-derived mesenchymal stem cells (BMCs) showed impaired angiogenesis along with downregulation of stem cell factor (SCF). This study was designed to determine the involvement of microRNAs (miR), which are actively involved in the physiological function of stem cells. We observed that miR-34c was significantly induced by high glucose treatment and blunted tube formation of BMCs. Stem cell factor (SCF) was confirmed as a target of miR-34c by 3'-UTR promoter analysis and Western blot. SCF knockdown by siRNA induced Krüppel-like factor 4 (KLF4) and resulted in the blockade of angiogenesis of BMCs. Sequentially, KLF4 overexpression completely blocked tube formation through inducing PAI-1 (plasminogen activator inhibitor-1). To study the action of miR-34c in terms of the therapeutic potential of BMCs, myocardial infarction (MI) was induced by ligation of the coronary artery in nude mice, BMCs transfected with miR-control or miR-34c were injected into the infarcted myocardium 7 days later, and histological studies were performed 2 weeks later. Cardiac fibrosis was 18.24±4.7% in the miR-34c-BMC group and 10.01±0.2% in the miR-control-BMC group (p<0.05). Cardiac function and vessel density were decreased in the miR-34c-BMC group compared with the miR-con-BMC group. Particularly, miR-34c-BMCs failed to incorporate into vessels. Our results show that the angiogenic activity of BMCs is finely regulated by the miR-34c-SCF-KLF4 axis, which is a potent translational target for optimizing the therapeutic activity of autologous BMCs for cardiac repair.

Citing Articles

The Role of ncRNAs in Cardiac Infarction and Regeneration.

Cano-Carrillo S, Lozano-Velasco E, Castillo-Casas J, Sanchez-Fernandez C, Franco D J Cardiovasc Dev Dis. 2023; 10(3).

PMID: 36975887 PMC: 10052289. DOI: 10.3390/jcdd10030123.


Extracellular vesicles derived from hypoxia-preconditioned bone marrow mesenchymal stem cells ameliorate lower limb ischemia by delivering miR-34c.

Peng X, Liu J, Ren L, Liang B, Wang H, Hou J Mol Cell Biochem. 2023; 478(7):1645-1658.

PMID: 36729282 DOI: 10.1007/s11010-023-04666-7.


Inducible miR-1224 silences cerebrovascular Serpine1 and restores blood flow to the stroke-affected site of the brain.

Palakurti R, Biswas N, Roy S, Gnyawali S, Sinha M, Singh K Mol Ther Nucleic Acids. 2023; 31:276-292.

PMID: 36726407 PMC: 9868883. DOI: 10.1016/j.omtn.2022.12.019.


Stem cells therapy in acute myocardial infarction: a new era?.

Carbone R, Monselise A, Bottino G, Negrini S, Puppo F Clin Exp Med. 2021; 21(2):231-237.

PMID: 33484381 PMC: 8053645. DOI: 10.1007/s10238-021-00682-3.


Systematic Analysis of tRNA-Derived Small RNAs Discloses New Therapeutic Targets of Caloric Restriction in Myocardial Ischemic Rats.

Liu W, Liu Y, Pan Z, Zhang X, Qin Y, Chen X Front Cell Dev Biol. 2020; 8:568116.

PMID: 33224944 PMC: 7670042. DOI: 10.3389/fcell.2020.568116.